Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate
Autor: | Hermann R. Ochs, Kate Franke, Henry J. Pfeifer, David J. Greenblatt, Thomas W. Smith, Elaine Woo |
---|---|
Rok vydání: | 1978 |
Předmět: |
Adult
Male Quinidine medicine.medical_specialty Administration Oral Absorption (skin) Pharmacology Gluconates chemistry.chemical_compound Quinidine Sulfate Pharmacokinetics Internal medicine Humans Medicine Sulfate Sulfates business.industry Quinidine Gluconate Crossover study Kinetics chemistry Anesthesia Cardiology Female Steady state (chemistry) Cardiology and Cardiovascular Medicine business Half-Life medicine.drug |
Zdroj: | The American Journal of Cardiology. 41:770-777 |
ISSN: | 0002-9149 |
Popis: | The pharmacokinetics of oral quinidine sulfate and quinidine gluconate were compared in seven healthy volunteers In a two part pharmacokinetic study. Part I was a single dose crossover trial assessing absorption and elimination of quinidine sulfate (400 mg, equivalent to 331 mg of quinidine base) and quinidine gluconate (495 mg, equivalent to 309 mg of quinidine base). Mean kinetic values for the sulfate and gluconate preparations, respectively, were: peak serum quinidine level 2.07 versus 1.24 μg/ml (P Part II evaluated steady state kinetics of both preparations in a cross-over trial in the same subjects. Maintenance dosing schedules were 200 mg of quinidine sulfate every 6 hours versus 495 mg of quinidine gluconate every 12 hours. Systemic availability of the gluconate at the steady state level was 10 percent less (based upon area under the serum concentration curve) or 7 percent less (based upon urinary excretion of quinidine) than that of the sulfate, but the differences were not significant. Interdose fluctuation in serum quinidine concentrations during the gluconate trial averaged 70 percent, which was not significantly different from the average of 67 percent during the sulfate trial. However, variation within and between subjects in minimal steady state levels with quinidine gluconate (15.6 and 16.0 percent, respectively) was greater than with quinidine sulfate (7.2 and 9.9 percent, respectively). Steady state concentrations during the multiple dose trial were not accurately predicted from single dose pharmacokinetics, either for quinidine sulfate (r = 0.45) or quinidine gluconate (r = −0.12), but deviation of observed from predicted concentrations tended to be greater with quinidine gluconate. The slow absorption of quinidine from the gluconate preparation allows maintenance therapy on a 12 hourly dosage schedule with acceptable interdose fluctuation in serum levels. Variability within and between subjects in absorption kinetics tends to be greater with quinidine gluconate than with the more rapidly absorbed sulfate salt. |
Databáze: | OpenAIRE |
Externí odkaz: |